The invention provides methods, compositions, and kits for the characterisation and analysis of proteins. Methods are provided for determining, on a protein, a binding site for a binding partner, the methods comprising: contacting a protein with a plurality of monomers, and polymerising the monomers to create a protein:polymer complex; digesting the protein in the complex to produce a peptide:polymer complex; isolating the peptide:polymer complex; and sequencing the peptide, wherein the peptide corresponds to a binding site for a binding partner.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention relates to a GPCR19-P2Xn receptor complex and use of the same, particularly to a method for screening a substance that regulates the interaction between GPCR19 and a P2Xn receptor in their complex; a method for screening a substance for prevention or treatment of an NLRP3 inflammasome-associated diseases utilizing the interaction between GPCR19 and a P2Xn receptor in their complex; and a method for preventing or treating an NLRP3 inflammasome-associated disease, which comprises administering to an individual a pharmaceutically effective amount of a substance that induces the interaction between GPCR19 and a P2Xn receptor in their complex.

Provided herein are methods for identifying cognate pairs of a ligand species and a receptor species. The methods comprise (a) providing a set of ligand species, wherein each ligand species is represented at least one time; (b) providing a set of receptor species, wherein each receptor species is represented at least one time; (c) contacting the set of ligand species with the set of receptor species in a microreactor, wherein upon selective binding of a ligand species with a receptor species an enhanced signal is produced; (d) detecting a cognate pair of ligand species and receptor species by the production of the enhanced signal; and (a) identifying the cognate pair of ligand species and receptor species.

Neoantigens play a key role in the recognition of tumor cells by T cells. However, only a small proportion of neoantigens truly elicit T cell responses, and fewer clues exist as to which neoantigens are recognized by which T cell receptors (TCRs). To help determine the TCRs that interact with particular neoantigens, prediction models that predict TCR-binding specificities of neoantigens presented by different classes of major histocompatibility complex (MHCs) were developed. To confirm the applicability of the model to clinical settings, the prediction models were comprehensively validated by a series of analyses. The validated prediction models used a flexible transfer learning approach and differential learning schema to achieve highly accurate prediction of TCR binding specificity only using TCR sequence data, antigen sequence data, and MHC alleles.

Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).